International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma
Rattachement africain : dk, rs. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: The International prognostic index (IPI) is a widely used model for identifying trial-eligible patients with diffuse large B-cell lymphoma (DLBCL). However, the applicability of prognostic models in identifying trial-eligible high-intermediate (HI) and high-risk (H), particularly younger patients, has not been extensively studied. METHODS: Patients with newly diagnosed DLBCL were identified in the Danish Lymphoma Registry (LYFO). To evaluate the impact of IPI and age-adjusted IPI (aaIPI) on identifying higher-risk (HI and H-risk) trial-eligible patients, we retrieved the eligibility criteria for the frontMIND trial (NCT04824092). RESULTS: Of 6252 patients with DLBCL registered in the LYFO, 3725 (59.6%) were trial-eligible. The dataset included all IPI/aaIPI groups. However, 46% of 3725 patients would meet trial eligibility if IPI and aaIPI higher-risk patients were selected. The 5-year progression-free (PFS) and overall survival (OS) were 61.7% and 70.5%, respectively. Among patients aged ≤ 60 years (35.5%; 1321/3725), 29.5% were frontMIND-eligible based on aaIPI, with 5-year PFS and OS of 72.3% and 82.8%, respectively. Combining IPI and aaIPI did not improve the identification of patients who did not respond to standard treatment, and utilizing this strategy for trial selection was not superior to using IPI or NCCN-IPI alone. CONCLUSIONS: Prognostic models can help in selecting trial-eligible HI and H-risk patients, thereby increasing the chances of identifying those who do not respond to standard treatment. However, the currently used prognostic indices fail to accurately recognize some high-risk patients, particularly young patients. Therefore, additional risk factors beyond prognostic models are needed to improve patient selection for trial participation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma
- Date Crossref
- 01/01/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Odense University Hospital Department of Hematology pays non établi dans la noticeOrganisme public
-
University of Belgrade Institute for Medical Statistics and Informatics pays non établi dans la noticeUniversité ou école supérieure
-
Aalborg University Hospital Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
Aalborg University pays non établi dans la noticeUniversité ou école supérieure
-
Vejle Sygehus pays non établi dans la noticeÉtablissement de santé
-
Lillebaelt Hospital pays non établi dans la noticeÉtablissement de santé
-
Aarhus University Hospital pays non établi dans la noticeÉtablissement de santé
-
Regionshospitalet Herning pays non établi dans la noticeÉtablissement de santé
-
Zealand University Hospital Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
Copenhagen University Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Southern Denmark pays non établi dans la noticeUniversité ou école supérieure
-
Vejle Hospital Department of Hematology pays non établi dans la noticeÉtablissement de santé
Department of Hematology — Odense University Hospital, Institute for Medical Statistics and Informatics — University of Belgrade et Department of Hematology — Aalborg University Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.